{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:02:41Z","timestamp":1788670961319,"version":"build-2803163510"},"reference-count":69,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Wroclaw Centre of Biotechnology, the Leading National Research Centre (KNOW) program for the years 2014\u20132018","award":["132\/2017\/KNOW\/IITD"],"award-info":[{"award-number":["132\/2017\/KNOW\/IITD"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Multiple myeloma (MM) is a hematologic malignancy characterized by severely profound immune dysfunction. Therefore, the efficacy of drugs targeting the immune environments, such as immune checkpoint inhibitors (ICIs), is of high clinical importance. However, several clinical trials evaluating ICIs in MM in different therapeutic combinations revealed underwhelming results showing a lack of clinical efficacy and excessive side effects. The underlying mechanisms of resistance to ICIs observed in the majority of MM patients are still under investigation. Recently, we demonstrated that inappropriate expression of PD-1 and CTLA-4 on CD4 T cells in active MM is associated with adverse clinical outcomes and treatment status. The aim of the current study was to determine the usefulness of immune checkpoint expression assessment as a predictive biomarker of the response to therapeutic inhibitors. For this purpose, along with checkpoint expression estimated by flow cytometry, we evaluated the time to progression (TTP) of MM patients at different clinical stages (disease diagnosis and relapse) depending on the checkpoint expression level; the cut-off point (dividing patients into low and high expressors) was selected based on the median value. Herein, we confirmed the defective levels of regulatory PD-1, CTLA-4 receptors, and the CD69 marker activation in newly diagnosed (ND) patients, whereas relapsed\/refractory patients (RR) exhibited their recovered values and reactivity. Additionally, substantially higher populations of senescent CD4+CD28\u2212 T cells were found in MM, primarily in NDMM subjects. These observations suggest the existence of two dysfunctional states in MM CD4 T cells with the predominance of immunosenescence at disease diagnosis and exhaustion at relapse, thus implying different responsiveness to the external receptor blockade depending on the disease stage. Furthermore, we found that lower CTLA-4 levels in NDMM patients or higher PD-1 expression in RRMM patients may predict early relapse. In conclusion, our study clearly showed that the checkpoint level in CD4 T cells may significantly affect the time to MM progression concerning the treatment status. Therefore, when considering novel therapies and potent combinations, it should be taken into account that blocking PD-1 rather than CTLA-4 might be a beneficial form of immunotherapy for only a proportion of RRMM patients.<\/jats:p>","DOI":"10.3390\/ijms24065730","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T03:33:57Z","timestamp":1679024037000},"page":"5730","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors"],"prefix":"10.3390","volume":"24","author":[{"given":"Anna","family":"Kulikowska de Na\u0142\u0119cz","sequence":"first","affiliation":[{"name":"Hematology and Hematological Oncology Department, Provincial Hospital, 45-061 Opole, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5135-6336","authenticated-orcid":false,"given":"Lidia","family":"Ciszak","sequence":"additional","affiliation":[{"name":"Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Usnarska-Zubkiewicz","sequence":"additional","affiliation":[{"name":"Department of Hematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0386-7940","authenticated-orcid":false,"given":"Edyta","family":"Pawlak","sequence":"additional","affiliation":[{"name":"Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Frydecka","sequence":"additional","affiliation":[{"name":"Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Szmyrka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Internal Diseases, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3805-9476","authenticated-orcid":false,"given":"Agata","family":"Kosmaczewska","sequence":"additional","affiliation":[{"name":"Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3109\/10428194.2013.825905","article-title":"Myeloma skews regulatory and pro-inflammatory T helper 17 cell balance in favor of a suppressive state","volume":"55","author":"Favaloro","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.3109\/10428194.2014.904511","article-title":"Myeloid derived suppressor cells are numerically, functionally, and phenotypically different in patients with multiple myeloma","volume":"55","author":"Favaloro","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.4161\/onci.22032","article-title":"Trogocytosis generates acquired regulatory T cells adding further complexity to the dysfunctional immune response in multiple myeloma","volume":"1","author":"Brown","year":"2012","journal-title":"Oncoimmunology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1182\/blood.V98.10.2992","article-title":"Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-\u03b21 and interleukin-10","volume":"98","author":"Brown","year":"2001","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1038\/bcj.2013.34","article-title":"Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T cell clones and a favourable Treg\/Th17 balance","volume":"3","author":"Bryant","year":"2013","journal-title":"Blood Cancer J."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kulikowska de Nalecz, A., Ciszak, L., Usnarska-Zubkiewicz, L., Frydecka, I., Pawlak, E., Szmyrka, M., and Kosmaczewska, A. (2021). Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179298"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1038\/bcj.2015.32","article-title":"The cellular immune system in myelogenesis: NK and T cells in the development of myeloma and their uses in immunotherapies","volume":"5","author":"Dosani","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1172\/JCI88169","article-title":"Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression","volume":"128","author":"Kawano","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.immuni.2012.08.021","article-title":"Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory","volume":"37","author":"Doering","year":"2012","journal-title":"Immunity"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/leu.2015.104","article-title":"The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase I study","volume":"29","author":"Suen","year":"2015","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Thangavadivel","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3389\/fimmu.2019.00111","article-title":"Is there a positive side to T cell exhaustion?","volume":"10","author":"Pawelec","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8941260","DOI":"10.1155\/2016\/8941260","article-title":"Effector, memory, and dysfunctional CD8+ T cell fates in the antitumor immune response","volume":"2016","author":"Reiser","year":"2016","journal-title":"J. Immunol. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nri2959","article-title":"Are senescence and exhaustion intertwined or unrelated processes that compromise immunity?","volume":"11","author":"Akbar","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7555\/JBR.31.20160168","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"32","author":"Webb","year":"2018","journal-title":"J. Biomed. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8021","DOI":"10.1200\/JCO.2018.36.15_suppl.8021","article-title":"A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed\/refractory multiple myeloma (RRMM): Keynote-183","volume":"36","author":"Mateos","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1200\/JCO.2018.36.15_suppl.8010","article-title":"A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-na\u00efve multiple myeloma (MM): Keynote-185","volume":"36","author":"Usmani","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"777","DOI":"10.21037\/atm.2020.02.65","article-title":"Checkpoint inhibitors and myeloma: Promises, deadlocks and new directions","volume":"8","author":"Bertamini","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Alkharabsheh, O., Trisel, Z., Badami, S., Aljama, M.A., and Sidiqi, M.H. (2022). Checkpoint inhibitors in multiple myeloma: Intriguing potential and unfulfilled promises. Cancers, 14.","DOI":"10.3390\/cancers14010113"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41423-019-0344-8","article-title":"Exhaustion and senescence: Two crucial dysfunctional states of T cells in the tumor microenvironment","volume":"17","author":"Zhao","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/ni.2981","article-title":"The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells","volume":"15","author":"Lanna","year":"2014","journal-title":"Nat. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s12185-018-2405-7","article-title":"Immunopathogenesis and immunotherapy of multiple myeloma","volume":"107","author":"Tamura","year":"2018","journal-title":"Int. J. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2016.84","article-title":"Multiple myeloma causes clonal T cell immunosenescence: Identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10238-019-00585-4","article-title":"PDCD1 and PDCD1LG1 polymorphisms affect the susceptibility to multiple myeloma","volume":"20","author":"Kasamatsu","year":"2020","journal-title":"Clin. Exp. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12253-011-9431-6","article-title":"Variations in suppressor molecule CTLA-4 gene are related to susceptibility to multiple myeloma in a Polish population","volume":"18","author":"Karabon","year":"2011","journal-title":"Pathol. Oncol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1046\/j.1365-2141.2001.02552.x","article-title":"Cytotoxic T-lymphocyte antigen-4 microsatellite polymorphism is associated with multiple myeloma","volume":"112","author":"Zheng","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1007\/s13277-015-4217-1","article-title":"Patients with chronic lymphocytic leukemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: The possible implications for immunotherapy with CTLA-4 blocking antibody","volume":"37","author":"Ciszak","year":"2016","journal-title":"Tumor Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: The dark side of tumor suppression","volume":"5","author":"Coppe","year":"2010","journal-title":"Annu. Rev. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ni.3665","article-title":"A sestrin-dependent Erk-Jnk-p38 MAPK activation complex inhibits immunity during aging","volume":"18","author":"Lanna","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41467-017-02689-5","article-title":"Regulatory T cells trigger effector T cell DNA damage and senescence caused by metabolic competition","volume":"9","author":"Liu","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.3389\/fimmu.2018.02306","article-title":"Immune checkpoints as therapeutic targets in autoimmunity","volume":"9","author":"Paluch","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2016-09-741629","article-title":"PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy","volume":"129","author":"Asano","year":"2017","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.immuni.2018.05.006","article-title":"PD-1 inhibitory receptor downregulates asparaginyl endopeptidase and maintains Foxp3 transcription factor stability in induced regulatory T cells","volume":"49","author":"Stathopoulou","year":"2018","journal-title":"Immunity"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.4049\/jimmunol.179.10.6514","article-title":"CD4+CD28null T cells in autoimmune disease: Pathogenic features and decreased susceptibility to immunoregulation","volume":"179","author":"Thewissen","year":"2007","journal-title":"J. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/0961203320917749","article-title":"CD4+CD28null T cells are expanded in moderately active systemic lupus erythematosus and secrete pro-inflammatory interferon gamma, depending on the Disease Activity Index","volume":"29","author":"Kosmaczewska","year":"2020","journal-title":"Lupus"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/cncr.21746","article-title":"Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic\/Th1 T cells demonstrating a squed TCR-V\u03b2 repertoire","volume":"106","author":"Almeida","year":"2006","journal-title":"Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00277-016-2859-8","article-title":"History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: A population-based study","volume":"96","author":"Lindqvist","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbacli.2016.05.004","article-title":"Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"6","author":"Shimanovsky","year":"2016","journal-title":"BBA Clin."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-020-00947-6","article-title":"Targeting immune checkpoints in hematological malignancies","volume":"13","author":"Salik","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.3324\/haematol.2017.185777","article-title":"Anti-PD-1 associated fulminate myocarditis after a single pembrolizumab dose: The role of occult pre-existing autoimmunity","volume":"103","author":"Villar","year":"2018","journal-title":"Haematologica"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"20846","DOI":"10.1038\/s41598-020-77941-y","article-title":"Quantitative and functional characteristics of circulating and bone marrow PD-1- and TIM-3-positive T cells in treated multiple myeloma patients","volume":"10","author":"Batorov","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/sj.leu.2400714","article-title":"The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma","volume":"11","author":"Brown","year":"1997","journal-title":"Leukemia"},{"key":"ref_46","first-page":"S26","article-title":"The role of T cells in myeloma","volume":"4","author":"Joshua","year":"2003","journal-title":"Hematol. J."},{"key":"ref_47","first-page":"840","article-title":"T cell receptor Vbeta repertoire usage and clonal expansion of T cells in chronic myelogenous leukemia","volume":"117","author":"Li","year":"2004","journal-title":"Chin. Med. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1182\/blood-2009-10-246991","article-title":"Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenstrom macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy","volume":"115","author":"Li","year":"2010","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/sj.leu.2404590","article-title":"Prevalence and clinical association of clonal T-cell expansion in Myelodysplastic Syndrome","volume":"21","author":"Painter","year":"2007","journal-title":"Leukemia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/leu.2008.23","article-title":"T-cell receptor V\u03b2 CDR3 oligoclonality frequently occurs in childhood refractory cytopenia (MDS-RC) and severe aplastic anemia","volume":"22","author":"Vries","year":"2008","journal-title":"Leukemia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.3109\/10428190903216804","article-title":"Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma","volume":"50","author":"Brown","year":"2009","journal-title":"Leuk. Lymph."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood.V98.9.2817","article-title":"Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+CD57+CD28\u2212 compartment","volume":"98","author":"Sze","year":"2001","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1158\/1078-0432.CCR-19-1714","article-title":"Marrow infiltrating regulatory T cells correlate with the presence of dysfunctional CD4+PD-1+ cells and inferior survival in patients with newly diagnosed multiple myeloma","volume":"26","author":"Alrasheed","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_55","first-page":"579","article-title":"Immune checkpoint inhibitor therapy in oncology: Current uses and future directions","volume":"4","author":"Tan","year":"2022","journal-title":"J. Am. Coll. Cardiol. Cardio Onc."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm.4308","article-title":"VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat. Med."},{"key":"ref_58","first-page":"529","article-title":"Therapeutic targeting of immune checkpoints with small molecule inhibitors","volume":"11","author":"Smith","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s42003-021-02191-1","article-title":"PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy","volume":"4","author":"Sasikumar","year":"2021","journal-title":"Commun. Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e2127691","DOI":"10.1080\/2162402X.2022.2127691","article-title":"A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-vaxx)","volume":"11","author":"Guo","year":"2022","journal-title":"Oncoimmunology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-15-0077-T","article-title":"HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade","volume":"3","author":"Woods","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.18632\/oncotarget.3216","article-title":"Prognostic and predictive value of PDL1 expression in breast cancer","volume":"6","author":"Sabatier","year":"2015","journal-title":"Oncotarget"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2217\/imt-2016-0014","article-title":"Epigenetic modifiers in immunotherapy: A focus on checkpoint inhibitors","volume":"8","author":"Thomas","year":"2016","journal-title":"Immunotherapy"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/bjh.13318","article-title":"Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents","volume":"169","author":"Frys","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","article-title":"Entinostat neutralizes myeloid-derived suppressor cells and enhances the anti-tumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma","volume":"23","author":"Orillion","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"35326","DOI":"10.18632\/oncotarget.15108","article-title":"Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: A phase 2 consortium\/stand up 2 cancer study","volume":"8","author":"Azad","year":"2017","journal-title":"Oncotarget"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1158\/0008-5472.CAN-15-2125","article-title":"Combining epigenetic and immunotherapy to combat cancer","volume":"76","author":"Chiappinelli","year":"2016","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/6\/5730\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:57:16Z","timestamp":1760122636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/6\/5730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,17]]},"references-count":69,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["ijms24065730"],"URL":"https:\/\/doi.org\/10.3390\/ijms24065730","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,17]]}}}